"Benzoxazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
OXAZINES with a fused BENZENE ring.
| Descriptor ID |
D048588
|
| MeSH Number(s) |
D03.383.533.249 D03.633.100.209
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzoxazines".
Below are MeSH descriptors whose meaning is more specific than "Benzoxazines".
This graph shows the total number of publications written about "Benzoxazines" by people in this website by year, and whether "Benzoxazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 4 | 2 | 6 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 3 | 5 |
| 2014 | 2 | 2 | 4 |
| 2015 | 7 | 2 | 9 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 6 | 7 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzoxazines" by people in Profiles.
-
Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024 Sep 03; 79(9):2369-2378.
-
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):385-392.
-
Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. HIV Med. 2024 Jul; 25(7):826-839.
-
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet HIV. 2023 06; 10(6):e363-e374.
-
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clin Infect Dis. 2023 04 17; 76(8):1492-1495.
-
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
-
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022 03; 88(3):883-893.
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.
-
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
-
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021 12 06; 73(11):e3902-e3909.